Data presented at ADA 2016 suggest Novo Nordisk and Eli Lilly’s novel meal-time insulin analogs will fail to scale the commercial heights of their predecessors.
By Rajan Sharma, Senior Analyst
16 July 2016
I joined Datamonitor Healthcare in late in 2013 after completing a Masters in Pharmacology from the University of Oxford...
Read full bio
While Novo Nordisk and Eli Lilly’s previous generation prandial insulins, NovoLog (insulin aspart) and Humalog (insulin lispro), have consistently posted blockbuster revenues, their respective next-generation products are unlikely to achieve such commercial heights on account of the limited benefit conferred by such products and evolving market dynamics within the insulin space. The rationale for these rapid-acting analogs is that the faster onset of action more closely mimics the post-prandial action of endogenous insulin than current mealtime insulins. This allows for reduced post-prandial glucose levels and more flexible dosing as patients could administer insulin post-meal. However, clinical data suggest the faster-acting insulins FIAsp (Novo Nordisk) and BioChaperone Lispro (Eli Lilly) offer only limited benefits over their predecessors with many purported advantages unlikely to prove clinically meaningful. The expected availability of biosimilar insulin lispro (SAR342434; Sanofi) and growing pricing pressures within the diabetes space will serve to restrict use.
Get your free demo of Datamonitor Healthcare today. Simply fill out the form to the right >>>